查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2015034

偏頭痛治療市場：2026-2032年全球市場預測（按藥物類別、類型、適應症、患者年齡層、分銷管道和最終用戶分類）

Migraine Drugs Market by Drug Class, Types, Indication, Patient Age Group, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年偏頭痛治療市場價值為 14 億美元，預計到 2026 年將成長至 14.9 億美元，複合年成長率為 8.34%，到 2032 年將達到 24.6 億美元。

主要市場統計數據
基準年 2025 14億美元
預計年份：2026年 14.9億美元
預測年份：2032年 24.6億美元
複合年成長率 (%) 8.34%

本報告全面概​​述了塑造現代偏頭痛治療格局的臨床創新、商業性趨勢和策略重點。

隨著相關人員尋求更有效、更易耐受的治療方案，偏頭痛在臨床、監管和商業領域持續受到關注。本執行摘要全面概述了偏頭痛的治療方法，整合了近期臨床進展、不斷發展的治療模式以及影響醫生處方整體情況的商業性應對措施。本導言概述了本報告檢驗的關鍵主題：藥物類別區分、劑型、通路、特定年齡層的需求以及政策和貿易措施對供應的影響。

作用機制的進步、監管調整以及數位科技在護理中的應用如何共同作用，重新定義偏頭痛治療的開發、取得和商業化。

在科學突破、監管進步以及患者和支付方期望轉變的推動下，偏頭痛的治療現狀正經歷著變革性的轉變。標靶CGRP路徑生物製藥的進展重塑了預防性治療的框架，而小分子調變器和選擇性5-羥色胺受體促效劑的出現則拓展了急性期治療的選擇。這些治療創新正在改變臨床診療流程，促使臨床醫生重新評估長期以來的處方習慣，並在耐受性更好、給藥更便捷的情況下，將新藥納入治療方案。

評估 2025 年美國關稅調整對供應鏈、成本和採購的累積影響，以及這些影響對偏頭痛藥物供應和商業計劃的溢出效應。

關稅政策將對藥品分銷和跨境供應鏈的經濟效益產生重大影響，而美國2025年關稅表的最新調整已導致採購、分銷和定價策略等一系列連鎖反應。擁有全球供應鏈的製造商被迫重新評估其採購政策，考察替代物流路線，並應對影響與批發商和一體化分銷網路合約談判的到貨成本波動。在許多情況下，製造商和經銷商正在重新審視其庫存策略，以降低進口關稅快速變化的風險。

透過比較藥物類別、給藥方法、通路、適應症和年齡層，提供基於詳細細分的洞察，從而實現策略優先排序和差異化。

細分市場分析揭示了不同藥物類別、給藥途徑、分銷管道、適應症和患者年齡層所面臨的臨床和商業性挑戰各不相同，從而影響藥物研發和市場准入的優先事項。在藥物類別方面，研究主要集中在CGRP單株抗體、地坦類藥物、麥角衍生物、吉泮類藥物、非類固醇抗發炎藥和曲坦類藥物上，並對CGRP單株抗體進行了更詳細的產品分析，包括eptinezumab、erenumab、fremanezumab和galcanezumab。此外，目前正在研究的藥物包括地坦類藥物（如拉米地坦）、麥角類衍生物（如Dihydroergotamine和麥角胺）、吉泮類衍生物（如阿托吉泮、Ibuprofen和休布羅吉泮）、Rizatriptan固醇抗發炎藥（如雙氯芬酸鈉芬酸、布洛芬和萘普生）以及曲坦類衍生物（如阿魯米曲坦、依來曲坦、氟伐曲坦、Sumatriptan、利札曲坦、舒馬曲坦和佐米曲坦）。此分類系統支援基於作用機制，對每種給藥途徑的療效、安全性、給藥頻率和支付方預期進行比較評估。

區域策略挑戰揭示了監管差異、支付方期望和醫療保健基礎設施如何影響每個全球市場的採用和獲取。

區域趨勢對臨床導入、監管時間表、報銷框架和商業性實施有顯著影響，美洲、歐洲、中東和非洲以及亞太地區呈現出不同的模式。在美洲，成熟的專科醫療網路、生物製藥的高普及率以及不斷發展的支付方框架，共同營造了一個有利於新型預防治療方法快速整合到臨床實踐中的環境，並輔以可靠的真實世界數據和價值證明。該地區的相關人員在藥物採納決策中往往優先考慮長期療效和患者報告結局，如果生產商能夠使證據生成與支付方的期望相符，則可以加快藥物的採納進程。

在不斷發展的偏頭痛治療市場中，企業採取的競爭和策略行動決定了其准入、滲透率和長期市場定位。

偏頭痛治療領域的競爭格局呈現出多元化的策略，涵蓋了從廣泛的產品組合和生命週期管理到針對性創新和夥伴關係各個方面。領先的生物製藥公司正透過利用其成熟的商業基礎設施並投資於長期實證項目，鞏固其在預防醫學領域的地位。這些公司通常採用廣泛的適應症策略，並結合患者支援舉措和綜合服務，以提高患者的用藥依從性，並確保患者在專業藥房順利取藥。

結合證據產生、數位支援和具有韌性的商業模式，提出切實可行的策略建議，以確保永續的獲取和傳播。

在偏頭痛治療領域尋求永續價值的行業領導者應採取多管齊下的方法，整合臨床證據、支付方參與和營運韌性。首先，應優先產生以患者為中心的真實世界數據，這些數據能夠補充隨機對照試驗的結果，並直接解答支付方關於療效永續性、不同人群安全性以及衛生經濟學結果等方面的疑問。此類證據構成了基於價值的對話的基礎，並有助於確保藥物在藥品目錄中獲得有利地位。

我們採用嚴謹且多方面的調查方法，結合與關鍵相關人員的訪談、系統性的文獻回顧和交叉檢驗的分析技術，得出可操作的見解。

本分析的調查方法整合了多種檢驗來源，以確保獲得穩健且多角度的洞見。主要研究包括對臨床醫生、保險公司、採購專業人員和行業高管進行結構化訪談，以了解他們在治療方法選擇方面的實際經驗、影響藥物採用決策的因素以及營運障礙。次要研究則系統地回顧了同行評審文獻、監管文件、臨床試驗註冊信息和上市公司資訊披露，以檢驗臨床概況、安全性訊號和產品平臺。

簡潔扼要的結論整合了創新、進入趨勢和策略重點，這些因素定義了現代偏頭痛治療領域的成功。

總之，目前偏頭痛治療的特點是：科學取得了顯著進展，商業模式不斷演進，支付方和患者對可衡量的療效期望日益提高。生物預防藥物、用於急性治療的標靶小分子藥物以及輔助性數位工具的融合正在重塑治療標準，並迫使相關人員採用更複雜的價值論證策略。在這種環境下取得成功，需要臨床差異化、實證醫學證據的產生和切實可行的商業性執行之間實現清晰的協調一致。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：偏頭痛治療市場：依藥物類別分類

  • CGRP單株抗體
    • 艾普汀珠單抗
    • 埃萊努單抗
    • 弗雷馬內珠單抗
    • 加爾卡內茲馬
  • 迪坦
  • 麥角衍生物
    • Dihydroergotamine
    • 麥角胺
  • 吉潘特系統
    • 阿特格潘斯
    • 霜化劑
    • Hublot Gepanto
  • NSAIDs
    • 雙氯芬酸鈉
    • Ibuprofen
    • 萘普生
  • 曲坦類藥物
    • 阿爾莫托利普坦
    • 依來曲坦
    • 氟巴曲坦
    • 那拉曲坦
    • Rizatriptan
    • Sumatriptan
    • 佐米曲坦

第9章：偏頭痛治療市場：依類型分類

  • 注射藥物
    • 靜脈
    • 皮下
  • 鼻腔
  • 口服
    • 膠囊
    • 藥片
  • 外用
  • 經皮吸收

第10章：偏頭痛治療市場：依適應症分類

  • 急性治療
  • 預防性治療

第11章 偏頭痛治療市場：依患者年齡層別分類

  • 成人
  • 兒童
    • 青年
    • 兒童
    • 新生

第12章：偏頭痛治療市場：依通路分類

  • 離線
  • 線上

第13章：偏頭痛治療市場：依最終用戶分類

  • 醫院和診所
  • 居家照護設施
  • 專業醫療中心

第14章：偏頭痛治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：偏頭痛治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 偏頭痛治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國偏頭痛治療市場

第18章：中國偏頭痛治療市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Impel Pharmaceuticals Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-036C5CF3A820

The Migraine Drugs Market was valued at USD 1.40 billion in 2025 and is projected to grow to USD 1.49 billion in 2026, with a CAGR of 8.34%, reaching USD 2.46 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.40 billion
Estimated Year [2026] USD 1.49 billion
Forecast Year [2032] USD 2.46 billion
CAGR (%) 8.34%

A comprehensive introduction that frames clinical innovations, commercial dynamics, and strategic priorities shaping the contemporary migraine therapeutics environment

Migraine continues to command attention across clinical, regulatory, and commercial forums as stakeholders pursue more effective and better tolerated therapeutic options. This executive summary introduces a holistic view of the migraine drugs landscape that integrates recent clinical advances, evolving treatment paradigms, and the commercial responses that shape prescriber behavior. The introduction frames the core topics examined in the report: drug-class differentiation, administration modalities, distribution pathways, age-segmented needs, and the influence of policy and trade measures on availability.

The rationale for a focused market study is rooted in the rapid pace of innovation coupled with persistent unmet needs. Patients frequently cycle through multiple acute and preventive regimens, and clinicians increasingly weigh long-term safety, adherence, and quality-of-life outcomes alongside efficacy. Consequently, product positioning now requires a nuanced understanding of how novel modalities and established therapies coexist in formularies and clinical practice. The report synthesizes these dynamics to support strategic positioning, clinical development prioritization, and commercialization planning.

To ensure relevance for diverse stakeholders, the introduction also clarifies the report's scope, the methodological approach used for evidence triangulation, and the types of deliverables available to subscribers. By setting a clear context for subsequent sections, this introduction prepares readers to interpret comparative insights on drug classes, administration routes, distribution strategies, patient segmentation, and regional differentials within a coherent analytical framework.

How breakthroughs in mechanism of action, regulatory adaptation, and digital-enabled care are jointly redefining development, access, and commercialization in migraine therapeutics

The migraine treatment landscape is undergoing transformative shifts driven by scientific breakthroughs, regulatory evolution, and changing expectations among patients and payers. Advances in biologics targeting CGRP pathways have reframed preventive care, while the arrival of small-molecule modulators and selective serotonin receptor agonists has expanded options for acute management. These therapeutic innovations are altering clinical algorithms, prompting clinicians to re-evaluate long-standing prescribing habits and to incorporate newer agents where improved tolerability or administration convenience offers tangible benefits.

Alongside pharmacologic progress, regulatory pathways are adapting to accommodate accelerated development timelines and novel endpoints that capture patient-centered outcomes, such as reduction in headache-related disability and improvements in daily functioning. Payers and formulary committees are responding to these changes by developing evidence requirements that emphasize real-world effectiveness and cost-effectiveness over short-term clinical endpoints. As a result, manufacturers are placing greater emphasis on post-authorization observational research and value-based contracting.

Commercial models are also shifting. Digital health tools, remote monitoring, and telemedicine are strengthening patient engagement and adherence programs, thus creating opportunities for integrated care models that pair therapeutics with services. Moreover, manufacturers are experimenting with differentiated reimbursement approaches and targeted education campaigns to drive appropriate use among specific patient cohorts. In summary, the combined force of novel mechanisms of action, evolving regulatory expectations, payer-driven evidence demands, and digital enablement is transforming how migraine therapies are developed, positioned, and delivered.

Assessing the cumulative supply chain, cost, and procurement effects of United States tariff adjustments in 2025 and their implications for migraine drug availability and commercial planning

Tariff policy can materially affect the movement of pharmaceutical goods and the economics of cross-border supply chains, and recent changes in United States tariff schedules in 2025 introduced adjustments that ripple through procurement, distribution, and pricing strategies. Manufacturers with global supply footprints have had to reassess sourcing decisions, evaluate alternative logistics corridors, and plan for variable landed costs that influence contracting discussions with wholesalers and integrated delivery networks. In many cases, manufacturers and distributors are rebalancing inventory strategies to mitigate the risk of step changes in import duties.

From a commercial perspective, tariff shifts can create short-term disruptions to product availability in specific channels and may alter the timing of promotional activities as companies adapt to revised cost structures. These dynamics can be particularly acute for therapies that rely on complex cold-chain logistics or specialized packaging that incurs higher customs processing scrutiny. Consequently, cross-functional teams are integrating tariff scenarios into scenario planning to preserve margin integrity while maintaining supply continuity.

On the regulatory and policy front, stakeholders are engaging with trade and industry associations to clarify classification codes, secure preferential treatment where applicable, and advocate for streamlined customs processes for medical products. Meanwhile, payers and institutional buyers are recalibrating procurement frameworks to ensure resilience, favoring suppliers who demonstrate robust contingency planning and transparent cost pass-through mechanisms. Ultimately, the cumulative impact of tariff adjustments is prompting a more strategic, risk-aware approach to supply chain design and commercial execution in the migraine drugs sector.

Deep segmentation-driven insights that compare drug classes, administration modalities, distribution pathways, indications, and age cohorts to inform strategic prioritization and differentiation

Segment-level analysis reveals distinct clinical and commercial imperatives across drug classes, administration routes, distribution channels, indications, and patient age groups that shape prioritization for development and market access. By drug class, the landscape is studied across CGRP monoclonal antibodies, ditans, ergot derivatives, gepants, NSAIDs, and triptans, with CGRP monoclonals further analyzed by products such as eptinezumab, erenumab, fremanezumab, and galcanezumab, ditans centered on lasmiditan, ergot derivatives examined through dihydroergotamine and ergotamine, gepants reviewed across atogepant, rimegepant, and ubrogepant, NSAIDs considered through diclofenac, ibuprofen, and naproxen, and triptans explored via almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan. This taxonomy supports comparative assessment of mechanism-driven efficacy, safety profiles, dosing frequency, and pathway-specific payer expectations.

In terms of route of administration, the market is studied across injectable, nasal, oral, topical, and transdermal modalities, with injectables further broken down into intravenous and subcutaneous forms and orals differentiated between capsule and tablet presentations. Route considerations influence patient adherence, administration burden, and opportunities for clinic-based versus home-based care models. Distribution channel segmentation distinguishes offline and online pathways, reflecting distinct purchasing behaviors, formulary access patterns, and opportunities for digital engagement that affect uptake velocity and adherence support.

Indication segmentation separates acute treatment from preventive treatment, highlighting differences in clinical trial designs, endpoint selection, and reimbursement criteria. Patient age group segmentation covers adult and pediatric populations, with pediatric analysis further segmented into adolescents, children, and neonates to ensure age-appropriate safety, dosing, and route considerations. Together, these segmentation lenses enable nuanced insight into where clinical differentiation, commercial investment, and regulatory focus are most consequential.

Regional strategic imperatives revealing how regulatory heterogeneity, payer expectations, and healthcare infrastructure shape adoption and access across global markets

Regional dynamics profoundly influence clinical adoption, regulatory timelines, reimbursement frameworks, and commercial execution, with distinct patterns observable across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established specialty care networks, high rates of biologic uptake, and evolving payer frameworks create an environment where novel preventive treatments can rapidly integrate into clinical practice when supported by robust real-world evidence and value demonstration. Stakeholders in the region often prioritize long-term outcomes and patient-reported measures in formulary decisions, which can accelerate adoption when manufacturers align evidence generation with payer expectations.

In Europe, Middle East & Africa, regulatory heterogeneity and diverse reimbursement models shape launch sequencing and pricing strategies. National health technology assessment bodies and centralized regulatory pathways exert significant influence, prompting manufacturers to tailor entry strategies that reconcile clinical benefit with cost-effectiveness assessments. Meanwhile, markets across the Middle East and Africa may present access challenges due to infrastructural variability, emphasizing the need for innovative distribution partnerships and capacity building.

The Asia-Pacific region exhibits a wide spectrum of maturity in specialty care and payer sophistication, with several markets demonstrating rapid uptake of novel therapies when local clinical data and affordability programs support access. Local regulatory requirements and variations in healthcare financing necessitate adaptive market entry plans, including considerations for manufacturing localization, tiered pricing, and collaboration with regional distributors. Overall, regional insights underscore the importance of aligning evidence generation, commercial models, and supply-chain resilience with the unique structural characteristics of each geography.

Competitive and strategic company behaviors that determine access, uptake, and long-term positioning in the evolving migraine therapeutics market

Competitive dynamics among companies operating in the migraine therapeutics space reflect varied strategies that range from portfolio breadth and lifecycle management to targeted innovation and partnerships. Large biopharmaceutical firms are consolidating their foothold in preventive care by leveraging established commercial infrastructures and investing in long-term evidence-generation programs. These players often pursue broad-label strategies, coupled with patient-support initiatives and integrated services that facilitate adherence and specialty dispensing.

Niche and mid-sized companies are concentrating on differentiated mechanisms of action, convenience of administration, and specific patient subpopulations where clinical differentiation can justify premium positioning. Partnerships between innovators and contract manufacturing or distribution partners are increasingly common, enabling agility in supply-chain scaling while allowing smaller firms to focus on clinical development and market access strategies. Strategic alliances between pharmaceutical companies and digital-health vendors are also on the rise, reflecting a shift toward bundled propositions that combine medication with adherence and monitoring tools.

Across the competitive landscape, companies that demonstrate a clear evidence generation roadmap, a flexible pricing approach, and strong relationships with specialty care networks and payers tend to secure favorable access outcomes. In addition, organizations that proactively manage regimen-switching patterns, optimize patient initiation pathways, and support clinicians with concise, outcome-focused datasets are better positioned to achieve durable uptake. Observing these strategic behaviors provides a practical template for companies aiming to refine their market entry or expansion approaches.

Actionable strategic recommendations that combine evidence generation, digital-enabled support, and resilient commercial models to secure durable access and uptake

Industry leaders seeking to capture sustainable value in migraine therapeutics should pursue multifaceted actions that integrate clinical evidence, payer engagement, and operational resilience. First, prioritize generation of patient-centered real-world data that complements randomized controlled trial results and directly addresses payer questions about durability of effect, safety in heterogeneous populations, and health-economic outcomes. Such evidence will underpin value-based conversations and help secure favorable formulary positioning.

Second, develop differentiated patient support and adherence programs that leverage digital tools to reduce barriers to initiation and continuation of therapy. Integrated care pathways that combine clinician education, remote monitoring, and streamlined access processes can materially improve persistence and patient satisfaction, thereby reinforcing clinical and economic value propositions. Third, build flexible commercial strategies that account for regional regulatory variation and tariff-related supply-chain risk; this includes diversifying manufacturing and distribution partners, investing in local regulatory expertise, and incorporating tariff scenarios into scenario planning.

Finally, pursue collaborative arrangements with payers and health systems, such as outcomes-based agreements or risk-sharing models, where feasible and supported by robust outcomes measurement. Such partnerships can accelerate access while aligning incentives around measurable patient benefit. Taken together, these actions support a resilient, evidence-driven approach to market entry and lifecycle management that balances short-term uptake with long-term value realization.

A rigorous, multi-source research methodology combining primary stakeholder interviews, systematic literature review, and cross-validated analytical techniques to produce actionable insights

The research methodology underpinning this analysis integrates multiple evidence streams to ensure robust, triangulated insights. Primary research included structured interviews with clinicians, payers, procurement specialists, and industry executives to capture lived experience with therapeutic choices, formulary decision drivers, and operational barriers. Secondary research encompassed a systematic review of peer-reviewed literature, regulatory documents, clinical trial registries, and public company disclosures to validate clinical profiles, safety signals, and product pipelines.

Analytical techniques involved cross-validation of qualitative inputs against secondary sources, thematic coding of interview content to identify recurring barriers and enablers, and the development of segmentation matrices that map clinical utility to commercial levers. Supply-chain and tariff impact assessments drew on customs classifications, logistics workflows, and expert consultations to model potential operational responses without attempting to forecast specific market figures. Quality assurance processes included peer review by therapeutic area experts and reconciliation of conflicting data points through follow-up interviews.

By synthesizing diverse evidence streams and applying transparent analytic logic, the methodology provides a defensible basis for the insights and recommendations presented. The approach balances depth and practicality, designed to inform decision makers who require actionable intelligence rather than high-level summaries alone.

A concise conclusion synthesizing innovation, access dynamics, and strategic priorities that define success in the contemporary migraine therapeutics arena

In closing, the migraine therapeutics landscape is characterized by meaningful scientific progress, evolving commercial models, and heightened expectations from payers and patients for measurable outcomes. The convergence of biologic preventive agents, targeted small molecules for acute care, and supportive digital tools reshapes standards of care and compels stakeholders to adopt more sophisticated value demonstration strategies. Success in this environment requires a clear alignment between clinical differentiation, evidence generation, and pragmatic commercial execution.

Manufacturers and investors should view the current period as one of opportunity that rewards disciplined evidence planning, nimble supply-chain strategies, and constructive payer engagement. Meanwhile, clinicians and patient advocates benefit from an expanding therapeutic toolkit that can be tailored to individual patient preferences and tolerability requirements. As the sector evolves, sustained emphasis on real-world outcomes, adherence support, and collaborative access models will determine which innovations translate into meaningful improvements in patient care.

Taken together, the insights in this executive summary provide a platform for immediate action and longer-term planning. Stakeholders who leverage these perspectives to refine development strategies, optimize market access approaches, and strengthen operational resilience will be best positioned to capture the clinical and commercial potential arising from ongoing innovation in migraine treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Migraine Drugs Market, by Drug Class

  • 8.1. Cgrp Monoclonal Antibodies
    • 8.1.1. Eptinezumab
    • 8.1.2. Erenumab
    • 8.1.3. Fremanezumab
    • 8.1.4. Galcanezumab
  • 8.2. Ditans
  • 8.3. Ergot Derivatives
    • 8.3.1. Dihydroergotamine
    • 8.3.2. Ergotamine
  • 8.4. Gepants
    • 8.4.1. Atogepant
    • 8.4.2. Rimegepant
    • 8.4.3. Ubrogepant
  • 8.5. Nsaids
    • 8.5.1. Diclofenac
    • 8.5.2. Ibuprofen
    • 8.5.3. Naproxen
  • 8.6. Triptans
    • 8.6.1. Almotriptan
    • 8.6.2. Eletriptan
    • 8.6.3. Frovatriptan
    • 8.6.4. Naratriptan
    • 8.6.5. Rizatriptan
    • 8.6.6. Sumatriptan
    • 8.6.7. Zolmitriptan

9. Migraine Drugs Market, by Types

  • 9.1. Injectable
    • 9.1.1. Intravenous
    • 9.1.2. Subcutaneous
  • 9.2. Nasal
  • 9.3. Oral
    • 9.3.1. Capsule
    • 9.3.2. Tablet
  • 9.4. Topical
  • 9.5. Transdermal

10. Migraine Drugs Market, by Indication

  • 10.1. Acute Treatment
  • 10.2. Preventive Treatment

11. Migraine Drugs Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Pediatric
    • 11.2.1. Adolescents
    • 11.2.2. Children
    • 11.2.3. Neonates

12. Migraine Drugs Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Migraine Drugs Market, by End User

  • 13.1. Hospitals & Clinics
  • 13.2. Home Care Settings
  • 13.3. Specialty Centers

14. Migraine Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Migraine Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Migraine Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Migraine Drugs Market

18. China Migraine Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. AbbVie Inc.
  • 19.7. Amgen Inc.
  • 19.8. AstraZeneca PLC
  • 19.9. Bausch Health Companies Inc.
  • 19.10. Dr. Reddy's Laboratories Ltd.
  • 19.11. Eisai Co., Ltd.
  • 19.12. Eli Lilly and Company
  • 19.13. GlaxoSmithKline plc
  • 19.14. H. Lundbeck A/S
  • 19.15. Impel Pharmaceuticals Inc.
  • 19.16. Johnson & Johnson
  • 19.17. Merck & Co., Inc.
  • 19.18. Novartis AG
  • 19.19. Pfizer Inc.
  • 19.20. Sanofi S.A.
  • 19.21. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MIGRAINE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MIGRAINE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY EPTINEZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY EPTINEZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY EPTINEZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERENUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERENUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERENUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FREMANEZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FREMANEZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FREMANEZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GALCANEZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GALCANEZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GALCANEZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DITANS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DITANS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DITANS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ATOGEPANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ATOGEPANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ATOGEPANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIMEGEPANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIMEGEPANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIMEGEPANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY UBROGEPANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY UBROGEPANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY UBROGEPANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DICLOFENAC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DICLOFENAC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NAPROXEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ALMOTRIPTAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ALMOTRIPTAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ALMOTRIPTAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ELETRIPTAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ELETRIPTAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ELETRIPTAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FROVATRIPTAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FROVATRIPTAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FROVATRIPTAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NARATRIPTAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NARATRIPTAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NARATRIPTAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ZOLMITRIPTAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ZOLMITRIPTAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ZOLMITRIPTAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ACUTE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ACUTE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHILDREN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NEONATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NEONATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NEONATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 288. ASEAN MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 289. ASEAN MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 290. ASEAN MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. GCC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. GCC MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 293. GCC MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 294. GCC MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 295. GCC MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 296. GCC MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 297. GCC MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 298. GCC MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 299. GCC MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 300. GCC MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 301. GCC MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 302. GCC MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 303. GCC MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 304. GCC MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. GCC MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 318. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 320. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 330. BRICS MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 331. BRICS MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 332. BRICS MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 333. BRICS MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 334. BRICS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 335. BRICS MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 336. G7 MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 337. G7 MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 338. G7 MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 339. G7 MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 340. G7 MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 341. G7 MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 342. G7 MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 343. G7 MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
  • TABLE 344. G7 MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 345. G7 MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 346. G7 MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 347. G7 MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 348. G7 MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 349. G7 MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 350. G7 MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 351. NATO MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 352. NATO MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 353. NATO MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 354. NATO MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 355. NATO MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
  • TABLE 356. NATO MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 357. NATO MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
  • TABLE 358. NATO MIGRAINE